Abstract
The barrier to better drug treatment for children in low- and middle-income countries (LMICs) is not just a shortage of resources or the fact that diagnosis, prescription, and transport of selected drugs to patients is often impeded. The challenge is more complex. Some lessons learned in the developed world can be used in LMIC, including those pertaining to the application of dosing guidelines and the development of appropriate pediatric formulations. However, the challenge is not just about transfer of knowledge, experience, and wealth from countries that are rich to countries that are poor. In order to understand the magnitude of the problem and to see where the pharmaceutical industry could do more requires in-depth analysis. The author has identified a number of priorities for improved pharmaceutical company interaction with nongovernmental organizations, academic institutions. and philanthropies. Most of the goals cited are achievable if there is a shared will to better serve the needs of children.
Keywords
- Acute Lymphocytic Leukemia
- Pharmaceutical Industry
- Human African Trypanosomiasis
- Buruli Ulcer
- Modern Drug
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Hilts PJ. Protecting America’s heath. New York: Alfred A Knopf; 2003. ISBN 0-375-40466-X.
Rose K. Pediatric pharmaceutical legislation in the USA and EU and their impact on adult and pediatric drug development. In: Bar-Shalom D, Rose K, editors. Pediatric formulations – a roadmap. New York: Springer; 2014. p. 365–76. ISBN 978-1-4899-8010-6.
Rose K. Clinical testing in children. In: Bar-Shalom D, Bar-Shalom D, Rose K, editors. Pediatric formulations – a roadmap. New York: Springer; 2014. p. 405–20. ISBN 978-1-4899-8010-6.
Shirkey H. Editorial comment. Therapeutic orphans. J Pediatr. 1968;72:119–20. http://pediatrics.aappublications.org/content/104/Supplement_3/583.full.html. Accessed 13 Oct 2014.
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). www.ifpma.org. Accessed 13 Oct 2014.
Luetkemeyer A. Tuberculosis and HIV; 2013. http://hivinsite.ucsf.edu/InSite?page=kb-00&doc=kb-05-01-06. Accessed 13 Oct 2014.
Moreno S, Aldeguer JL, Arribas JR, Domingo P, Iribarren JA, Ribera E, et al. on behalf of thje HIV 2020 Project. The future of antiretroviral therapy: challenges and needs. J Antimicrob Chemother. 2010;65:827–35. http://jac.oxfordjournals.org/content/65/5/827.full.pdf+html. Accessed 13 Oct 2014.
Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanità. 2011;47:44–8. http://www.iss.it/publ/anna/2011/1/47144.pdf. Accessed 13 Oct 2014.
Henry D, Lexchin J. The pharmaceutical industry as a medicines provider. Lancet. 2002;360:1590–5. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)11527-3/fulltext. Accessed 13 Oct 2014. http://press.thelancet.com/childhoodcancer1.pdf. Accessed 13 Oct 2014.
Rodriguez W, Maldonado S. United States paediatric legislation impact on paediatric drug studies. In: Rose K, van den Anker JN, editors. Guide to paediatric drug development and clinical research. Basel: Karger Publishers; 2010. ISBN 978-3-8055-9362-5.
Rose K. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer. Clin Ther. 2014;36:163–77. http://www.clinicaltherapeutics.com/article/S0149-2918(14)00018-6/pdf. Accessed 13 Oct 2014.
Pritchard-Jones K, Pieters R, Reaman GH, Hjorth P, Downie G, Calaminus G, et al. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol. 2013;14:e95–103.
Vassal G, Zwaan CM, Ashley D. Improving cancer care for children and young people 3 – new drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol. 2013;14:e117–24. http://press.thelancet.com/childhoodcancer3.pdf. Accessed 13 Oct 2014.
Tassinari M. Pediatric Regulations 2012. Permanenpt laws and new provisions under FDASIA. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM332078.pdf. Accessed 13 Oct 2014.
Watts G. WHO launches campaign to make drugs safer for children. Br Med J. 2007;335:1227. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2137042/. Accessed 13 Oct 2014.
World Health Organization. Medicines for children. Fact sheet 341, June 2010.
World Health Organization. WHO model list of essential medicines for children. 2013. http://www.who.int/medicines/publications/essentialmedicines/4th_EMLc_FINAL_web_8Jul13.pdf. Accessed 13 Oct 2014.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Rose, K. (2015). Perspective on the Role of the Pharmaceutical Industry. In: MacLeod, S., Hill, S., Koren, G., Rane, A. (eds) Optimizing Treatment for Children in the Developing World. Adis, Cham. https://doi.org/10.1007/978-3-319-15750-4_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-15750-4_21
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-15749-8
Online ISBN: 978-3-319-15750-4
eBook Packages: MedicineMedicine (R0)